Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARS Pharmaceuticals, Inc.SPRY · Entity 883 | Director | June 24, 2026 | June 26, 2026 |
| Nautilus Biotechnology, Inc.ARYA · Entity 6679 | Director | August 06, 2020 | August 07, 2020 |
| Passage BIO, Inc.PASG · Entity 7829 | Director | May 28, 2025 | May 30, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARS Pharmaceuticals, Inc.
Report date June 24, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.54 · Expires 2036-06-23 | Direct | 30,000 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.
Nautilus Biotechnology, Inc.
Report date August 06, 2020 · Filed August 07, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-08-06 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-239986) under the heading "Description of Securities--Founder Shares", the shares of Class B ordinary shares, par value $0.0001 per share, will automatically convert into shares of Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-239986) under the heading "Description of Securities--Founder Shares", the shares of Class B ordinary shares, par value $0.0001 per share, will automatically convert into shares of Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
Passage BIO, Inc.
Report date May 28, 2025 · Filed May 30, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.36 · Expires 2035-05-28 | Direct | 201,857 |
Reported balance
After 2025-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-28 · Grant · Acquired 201,857 · Balance 201,857 F1: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2026 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2026 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SpringWorks Therapeutics, Inc.
Report date July 01, 2025 · Filed July 02, 2025
Section 16 reporting ended · disclosed 2025-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 1
1 source rowRow 1 · 2025-07-01 · Disposition to issuer · Disposed 954,869 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F2: Includes 162,414 shares underlying restricted stock units (each, an "RSU") granted under the Issuer's 2019 Stock Option and Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of Issuer common stock. F3: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and automatically converted into the right to receive $47.00 in cash, without interest and subject to any required tax withholding (the "Merger Consideration"). F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding RSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such RSU multiplied by (ii) the total number of shares of Issuer common stock subject to such RSU immediately prior to the Effective Time (each a "Parent Cash-Based RSU Award"). Each Parent Cash-Based RSU Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such RSU immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based RSU Award will vest, subject to the applicable holder's continued employment with Parent through such date. |
| Performance Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-07-01 · Disposition to issuer · Disposed 579,749 · Balance 0 F5: Represents restricted share units subject to performance-based vesting conditions (each, a "PSU") granted under the Plan. Each PSU represents a contingent right to receive one share of Issuer common stock. F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding PSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such PSU multiplied by (ii) the total number of shares of Issuer common stock subject to any such PSU immediately prior to the Effective Time that vests based on the achievement of performance levels determined in accordance with the applicable PSU award agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-07-01 · Disposition to issuer · Disposed 22,760 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.30 | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-07-01 · Disposition to issuer · Disposed 769,804 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.30 | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-07-01 · Disposition to issuer · Disposed 176,411 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.66 | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-07-01 · Disposition to issuer · Disposed 325,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.64 | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-07-01 · Disposition to issuer · Disposed 260,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.40 | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-07-01 · Disposition to issuer · Disposed 250,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.00 | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-07-01 · Disposition to issuer · Disposed 109,329 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger").
F2: Includes 162,414 shares underlying restricted stock units (each, an "RSU") granted under the Issuer's 2019 Stock Option and Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of Issuer common stock.
F3: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and automatically converted into the right to receive $47.00 in cash, without interest and subject to any required tax withholding (the "Merger Consideration").
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding RSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such RSU multiplied by (ii) the total number of shares of Issuer common stock subject to such RSU immediately prior to the Effective Time (each a "Parent Cash-Based RSU Award"). Each Parent Cash-Based RSU Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such RSU immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based RSU Award will vest, subject to the applicable holder's continued employment with Parent through such date.
F5: Represents restricted share units subject to performance-based vesting conditions (each, a "PSU") granted under the Plan. Each PSU represents a contingent right to receive one share of Issuer common stock.
F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding PSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such PSU multiplied by (ii) the total number of shares of Issuer common stock subject to any such PSU immediately prior to the Effective Time that vests based on the achievement of performance levels determined in accordance with the applicable PSU award agreement.
F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)
F8: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2026 Filed Jun 26, 2026 20:15 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $10.54 | $0.00 |
DisclosureSEC source: 0001575408-26-000002 · form4-06262026_040610.xml · derivative · entry 1 Islam Saqib · CIK 0001575408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-06-23 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:18 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 109,329 | Not disclosed Strike: $43.00 | Not disclosed |
DisclosureSEC source: 0001104659-25-065298 · tm2519678-2_4seq1.xml · derivative · entry 9 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 109,329 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · price: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.exercise_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.expiration_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:18 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 250,000 | Not disclosed Strike: $38.40 | Not disclosed |
DisclosureSEC source: 0001104659-25-065298 · tm2519678-2_4seq1.xml · derivative · entry 8 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · price: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.exercise_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.expiration_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:18 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 260,000 | Not disclosed Strike: $27.64 | Not disclosed |
DisclosureSEC source: 0001104659-25-065298 · tm2519678-2_4seq1.xml · derivative · entry 7 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 260,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · price: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.exercise_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.expiration_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:18 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 325,000 | Not disclosed Strike: $33.66 | Not disclosed |
DisclosureSEC source: 0001104659-25-065298 · tm2519678-2_4seq1.xml · derivative · entry 6 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 325,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · price: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.exercise_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.expiration_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:18 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 176,411 | Not disclosed Strike: $2.30 | Not disclosed |
DisclosureSEC source: 0001104659-25-065298 · tm2519678-2_4seq1.xml · derivative · entry 5 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 176,411 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · price: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.exercise_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.expiration_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:18 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 769,804 | Not disclosed Strike: $2.30 | Not disclosed |
DisclosureSEC source: 0001104659-25-065298 · tm2519678-2_4seq1.xml · derivative · entry 4 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 769,804 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · price: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.exercise_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.expiration_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:18 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 22,760 | Not disclosed Strike: $1.65 | Not disclosed |
DisclosureSEC source: 0001104659-25-065298 · tm2519678-2_4seq1.xml · derivative · entry 3 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,760 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · price: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.exercise_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.expiration_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:18 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Disposition to issuerPerformance Share Units · Derivative | 579,749 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-065298 · tm2519678-2_4seq1.xml · derivative · entry 2 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 579,749 shares Expires not disclosed F5 · derivative.exercise_price: Represents restricted share units subject to performance-based vesting conditions (each, a "PSU") granted under the Plan. Each PSU represents a contingent right to receive one share of Issuer common stock. F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F6 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding PSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such PSU multiplied by (ii) the total number of shares of Issuer common stock subject to any such PSU immediately prior to the Effective Time that vests based on the achievement of performance levels determined in accordance with the applicable PSU award agreement. F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding PSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such PSU multiplied by (ii) the total number of shares of Issuer common stock subject to any such PSU immediately prior to the Effective Time that vests based on the achievement of performance levels determined in accordance with the applicable PSU award agreement. F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding PSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such PSU multiplied by (ii) the total number of shares of Issuer common stock subject to any such PSU immediately prior to the Effective Time that vests based on the achievement of performance levels determined in accordance with the applicable PSU award agreement. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:18 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Disposition to issuerCommon Stock | 954,869 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-065298 · tm2519678-2_4seq1.xml · nonDerivative · entry 1 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F2 · shares: Includes 162,414 shares underlying restricted stock units (each, an "RSU") granted under the Issuer's 2019 Stock Option and Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of Issuer common stock. F3 · price: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and automatically converted into the right to receive $47.00 in cash, without interest and subject to any required tax withholding (the "Merger Consideration"). F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding RSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such RSU multiplied by (ii) the total number of shares of Issuer common stock subject to such RSU immediately prior to the Effective Time (each a "Parent Cash-Based RSU Award"). Each Parent Cash-Based RSU Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such RSU immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based RSU Award will vest, subject to the applicable holder's continued employment with Parent through such date. Read SEC document |
| June 25, 2025 Filed Jun 27, 2025 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $17.26 | $0.00 |
DisclosureSEC source: 0001415889-25-018385 · form4-06272025_040608.xml · derivative · entry 1 Islam Saqib · CIK 0001575408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-06-24 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 25, 2026 or the date of the Issuer's 2026 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document |
| May 28, 2025 Filed May 30, 2025 23:28 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (right to buy) · Derivative | 201,857 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001415889-25-015056 · form4-05302025_110532.xml · derivative · entry 1 Islam Saqib · CIK 0001575408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,857 Underlying: Common Stock · 201,857 shares Expires 2035-05-28 F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2026 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 23:32 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 600 | $56.89 | $34,134.00 |
DisclosureSEC source: 0001104659-25-021005 · tm258294-1_4seq1.xml · nonDerivative · entry 6 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 954,869 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 23:32 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 1,400 | $56.13 | $78,587.60 |
DisclosureSEC source: 0001104659-25-021005 · tm258294-1_4seq1.xml · nonDerivative · entry 5 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 955,469 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.84 to $56.36. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 23:32 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 11,600 | $55.15 | $639,782.92 |
DisclosureSEC source: 0001104659-25-021005 · tm258294-1_4seq1.xml · nonDerivative · entry 4 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 956,869 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.70 to $55.68. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 23:32 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 23,600 | $54.24 | $1,280,134.80 |
DisclosureSEC source: 0001104659-25-021005 · tm258294-1_4seq1.xml · nonDerivative · entry 3 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 968,469 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.70 to $54.685. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 23:32 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 11,800 | $52.97 | $625,016.50 |
DisclosureSEC source: 0001104659-25-021005 · tm258294-1_4seq1.xml · nonDerivative · entry 2 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 992,069 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.70 to $53.64. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 27, 2025 Filed Mar 5, 2025 23:32 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Tax withholdingCommon Stock | 30,756 | $53.41 | $1,642,677.96 |
DisclosureSEC source: 0001104659-25-021005 · tm258294-1_4seq1.xml · nonDerivative · entry 1 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,003,869 Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 23:58 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 5,068 | $61.24 | $310,348.10 |
DisclosureSEC source: 0001104659-25-016617 · tm257488-3_4seq1.xml · nonDerivative · entry 2 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,034,625 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.93 to $61.57. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 23:58 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 24,260 | $60.10 | $1,458,052.69 |
DisclosureSEC source: 0001104659-25-016617 · tm257488-3_4seq1.xml · nonDerivative · entry 1 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,039,693 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.90 to $60.83. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 21:50 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 10,672 | $59.92 | $639,489.72 |
DisclosureSEC source: 0001104659-25-015218 · tm257083-2_4seq1.xml · nonDerivative · entry 1 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,063,953 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.90 to $60.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 12, 2025 Filed Feb 15, 2025 00:30 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Tax withholdingCommon Stock | 13,186 | $59.28 | $781,666.08 |
DisclosureSEC source: 0001104659-25-014376 · tm256757-1_4seq1.xml · nonDerivative · entry 2 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,074,625 Read SEC document |
| February 12, 2025 Filed Feb 15, 2025 00:30 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | GrantCommon Stock | 85,309 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-014376 · tm256757-1_4seq1.xml · nonDerivative · entry 1 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,087,811 F1 · security: This transaction represents the issuance of performance restricted stock units ("PSUs"). Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. The PSUs were originally granted on January 5, 2023, subject to the achievement of a certain performance based milestone within four years from the grant date, which milestone was achieved as a result of approval by the U.S. Food and Drug Administration of the Issuer's product candidate, GOMEKLI(TM), for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas. F2 · security: 28,436 PSUs shall vest immediately upon issuance, another 28,436 PSUs shall vest on the date that is 12 months following February 12, 2025 and the remaining 28,437 PSUs shall vest on the date that is the later of (i) 24 months following February 12, 2025 or (ii) the Measurement Period End Date (as defined below), subject to continued service to the Issuer by the Reporting Person as of each such vesting date; provided that, such remaining 28,437 PSUs shall be subject to an upwards or downwards adjustment described in the PSU award agreement. As used herein, "Measurement Period End Date" means the first to occur of (i) December 31, 2026 or (ii) the date of consummation of a Sale Event (as defined in Issuer's 2019 Stock Option and Equity Incentive Plan). F1 · kind: This transaction represents the issuance of performance restricted stock units ("PSUs"). Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. The PSUs were originally granted on January 5, 2023, subject to the achievement of a certain performance based milestone within four years from the grant date, which milestone was achieved as a result of approval by the U.S. Food and Drug Administration of the Issuer's product candidate, GOMEKLI(TM), for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas. F2 · kind: 28,436 PSUs shall vest immediately upon issuance, another 28,436 PSUs shall vest on the date that is 12 months following February 12, 2025 and the remaining 28,437 PSUs shall vest on the date that is the later of (i) 24 months following February 12, 2025 or (ii) the Measurement Period End Date (as defined below), subject to continued service to the Issuer by the Reporting Person as of each such vesting date; provided that, such remaining 28,437 PSUs shall be subject to an upwards or downwards adjustment described in the PSU award agreement. As used herein, "Measurement Period End Date" means the first to occur of (i) December 31, 2026 or (ii) the date of consummation of a Sale Event (as defined in Issuer's 2019 Stock Option and Equity Incentive Plan). Read SEC document |
| February 10, 2025 Filed Feb 13, 2025 00:58 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 48,000 | $53.30 | $2,558,236.80 |
DisclosureSEC source: 0001104659-25-012363 · tm256428-3_4seq1.xml · nonDerivative · entry 1 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,002,502 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 to $53.88. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 21:33 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | GrantStock Option (Right to Buy) · Derivative | 109,329 | $0.00 Strike: $43.00 | $0.00 |
DisclosureSEC source: 0001104659-25-003463 · tm253183-4_4seq1.xml · derivative · entry 2 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,329 Underlying: Common Stock · 109,329 shares Expires 2035-01-10 F2 · derivative.exercise_date: This option shall vest in forty-eight (48) equal monthly installments following January 10, 2025, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 21:33 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | GrantCommon Stock | 74,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-003463 · tm253183-4_4seq1.xml · nonDerivative · entry 1 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,050,502 F1 · kind: This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty-three percent (33%) to vest on January 10, 2026, another thirty-three percent (33%) to vest on January 10, 2027 and the remaining thirty-four percent (34%) to vest on January 10, 2028, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date. F1 · shares: This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty-three percent (33%) to vest on January 10, 2026, another thirty-three percent (33%) to vest on January 10, 2027 and the remaining thirty-four percent (34%) to vest on January 10, 2028, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 00:13 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Tax withholdingCommon Stock | 12,359 | $38.86 | $480,270.74 |
DisclosureSEC source: 0001104659-25-001770 · tm252237-3_4seq1.xml · nonDerivative · entry 3 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 975,668 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 00:13 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Tax withholdingCommon Stock | 12,872 | $38.19 | $491,581.68 |
DisclosureSEC source: 0001104659-25-001770 · tm252237-3_4seq1.xml · nonDerivative · entry 2 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 988,027 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| January 04, 2025 Filed Jan 8, 2025 00:13 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Tax withholdingCommon Stock | 13,469 | $38.19 | $514,381.11 |
DisclosureSEC source: 0001104659-25-001770 · tm252237-3_4seq1.xml · nonDerivative · entry 1 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,899 F1 · security: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:23 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 3,989 | $41.85 | $166,935.66 |
DisclosureSEC source: 0001104659-24-125534 · tm2430055-1_4seq1.xml · nonDerivative · entry 2 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,014,368 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.76 to $42.02. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:23 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 45,011 | $41.33 | $1,860,421.66 |
DisclosureSEC source: 0001104659-24-125534 · tm2430055-1_4seq1.xml · nonDerivative · entry 1 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,018,357 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.76 to $41.74. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 03, 2024 Filed Sep 4, 2024 20:05 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 6,692 | $42.07 | $281,549.84 |
DisclosureSEC source: 0001104659-24-096872 · tm2423359-2_4seq1.xml · nonDerivative · entry 3 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,063,368 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.58 to $42.47. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 03, 2024 Filed Sep 4, 2024 20:05 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 9,908 | $41.10 | $407,259.42 |
DisclosureSEC source: 0001104659-24-096872 · tm2423359-2_4seq1.xml · nonDerivative · entry 2 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,070,060 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.52 to $41.505. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 03, 2024 Filed Sep 4, 2024 20:05 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 32,400 | $40.10 | $1,299,223.80 |
DisclosureSEC source: 0001104659-24-096872 · tm2423359-2_4seq1.xml · nonDerivative · entry 1 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,079,968 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.52 to $40.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 21:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $7.73 | $0.00 |
DisclosureSEC source: 0001415889-24-018013 · form4-06242024_050609.xml · derivative · entry 1 Islam Saqib · CIK 0001575408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 20, 2025 or the date of the Issuer's 2025 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:08 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 400 | $42.09 | $16,837.00 |
DisclosureSEC source: 0001104659-24-068675 · tm2416457-3_4seq1.xml · nonDerivative · entry 4 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,112,368 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.09 to $42.10. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:08 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 6,600 | $41.40 | $273,246.60 |
DisclosureSEC source: 0001104659-24-068675 · tm2416457-3_4seq1.xml · nonDerivative · entry 3 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,112,768 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.0332 to $42.02. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:08 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 8,760 | $40.57 | $355,363.42 |
DisclosureSEC source: 0001104659-24-068675 · tm2416457-3_4seq1.xml · nonDerivative · entry 2 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,119,368 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.02 to $41.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:08 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | SaleCommon Stock | 33,240 | $39.40 | $1,309,665.97 |
DisclosureSEC source: 0001104659-24-068675 · tm2416457-3_4seq1.xml · nonDerivative · entry 1 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,128,128 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.02 to $40.0147. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F6 · balance_after: Due to an administrative error, the prior Form 4 underreported total ownership by 905,104 shares, but total ownership has been corrected in this Form 4. No reportable transaction was omitted from such filing. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:53 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (right to buy) · Derivative | 47,693 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001415889-24-014311 · form4-05232024_080531.xml · derivative · entry 1 Islam Saqib · CIK 0001575408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,693 Underlying: Common Stock · 47,693 shares Expires 2034-05-21 F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2025 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document |
| January 08, 2024 Filed Jan 9, 2024 02:12 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Tax withholdingCommon Stock | 17,904 | $41.53 | $743,553.12 |
DisclosureSEC source: 0001104659-24-002379 · tm242462-8_4seq1.xml · nonDerivative · entry 3 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,264 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs and does not represent a sale by the Reporting Person. F2 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs and does not represent a sale by the Reporting Person. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 02:12 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Tax withholdingCommon Stock | 12,885 | $37.96 | $489,114.60 |
DisclosureSEC source: 0001104659-24-002379 · tm242462-8_4seq1.xml · nonDerivative · entry 2 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 274,168 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs and does not represent a sale by the Reporting Person. F2 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs and does not represent a sale by the Reporting Person. Read SEC document |
| January 04, 2024 Filed Jan 9, 2024 02:12 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001104659-24-002379 · tm242462-8_4seq1.xml · derivative · entry 4 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2034-01-03 F3 · derivative.exercise_date: This option shall vest in forty-eight (48) equal monthly installments following January 4, 2024, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date. Read SEC document |
| January 04, 2024 Filed Jan 9, 2024 02:12 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | GrantCommon Stock | 88,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-002379 · tm242462-8_4seq1.xml · nonDerivative · entry 1 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 287,053 F1 · security: This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty-three percent (33%) to vest on January 4, 2025, another thirty-three percent (33%) to vest on January 4, 2026 and the remaining thirty-four percent (34%) to vest on January 4, 2027, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date. F1 · kind: This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty-three percent (33%) to vest on January 4, 2025, another thirty-three percent (33%) to vest on January 4, 2026 and the remaining thirty-four percent (34%) to vest on January 4, 2027, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date. F1 · shares: This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty-three percent (33%) to vest on January 4, 2025, another thirty-three percent (33%) to vest on January 4, 2026 and the remaining thirty-four percent (34%) to vest on January 4, 2027, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date. Read SEC document |
| November 30, 2023 Filed Dec 1, 2023 21:01 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | GrantCommon Stock | 199,053 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-122819 · tm2331963-1_4seq1.xml · nonDerivative · entry 1 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,053 F1 · security: This transaction represents the grant of performance restricted stock units ("PSUs"). Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. The PSUs were originally granted on January 5, 2023, subject to the achievement of a certain performance based milestone within four years from the grant date, which milestone was achieved as a result of approval by the U.S. Food and Drug Administration of the Issuer's lead product candidate, Ogsiveo, for the treatment of desmoid tumors. F2 · security: 66,351 PSUs shall vest on the date that is 15 months following November 30, 2023, another 66,351 PSUs shall vest on the date that is 27 months following November 30, 2023 and the remaining 66,351 PSUs shall vest on the date that is the later of (i) 39 months following November 30, 2023 or (ii) the Measurement Period End Date (as defined below), subject to continued service to the Issuer by the Reporting Person as of each such vesting date; provided that, such remaining 66,351 PSUs shall be subject to an upwards or downwards adjustment described in the PSU award agreement. As used herein, "Measurement Period End Date" means the first to occur of (i) December 31, 2026 or (ii) the date of consummation of a Sale Event (as defined in Issuer's 2019 Stock Option and Equity Incentive Plan). F1 · kind: This transaction represents the grant of performance restricted stock units ("PSUs"). Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. The PSUs were originally granted on January 5, 2023, subject to the achievement of a certain performance based milestone within four years from the grant date, which milestone was achieved as a result of approval by the U.S. Food and Drug Administration of the Issuer's lead product candidate, Ogsiveo, for the treatment of desmoid tumors. F2 · kind: 66,351 PSUs shall vest on the date that is 15 months following November 30, 2023, another 66,351 PSUs shall vest on the date that is 27 months following November 30, 2023 and the remaining 66,351 PSUs shall vest on the date that is the later of (i) 39 months following November 30, 2023 or (ii) the Measurement Period End Date (as defined below), subject to continued service to the Issuer by the Reporting Person as of each such vesting date; provided that, such remaining 66,351 PSUs shall be subject to an upwards or downwards adjustment described in the PSU award agreement. As used herein, "Measurement Period End Date" means the first to occur of (i) December 31, 2026 or (ii) the date of consummation of a Sale Event (as defined in Issuer's 2019 Stock Option and Equity Incentive Plan). Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 01:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001209191-23-040107 · doc4.xml · derivative · entry 1 Islam Saqib · CIK 0001575408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-06-26 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 27, 2024 or the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document |
| May 25, 2023 Filed May 26, 2023 20:26 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032546 · doc4.xml · derivative · entry 1 Islam Saqib · CIK 0001575408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2033-05-24 F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2024 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document |
| January 07, 2023 Filed Jan 10, 2023 21:07 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Tax withholdingCommon Stock | 4,097 | $26.41 | $108,201.77 |
DisclosureSEC source: 0001104659-23-002717 · tm232960-6_4seq1.xml · nonDerivative · entry 1 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 905,104 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock awards and does not represent a sale by the Reporting Person. F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock awards and does not represent a sale by the Reporting Person. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 22:01 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Tax withholdingCommon Stock | 8,400 | $27.52 | $231,168.00 |
DisclosureSEC source: 0001104659-23-002322 · tm232787-8_4seq1.xml · nonDerivative · entry 2 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 909,201 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. F2 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. F3 · balance_after: Reflects a correction to the total number of securities beneficially owned, previously reported on a Form 4/A filed on January 14, 2022. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 22:01 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | GrantStock Option (Right to Buy) · Derivative | 260,000 | $0.00 Strike: $27.64 | $0.00 |
DisclosureSEC source: 0001104659-23-002322 · tm232787-8_4seq1.xml · derivative · entry 3 Islam Saqib · CIK 0001575408 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Stock · 260,000 shares Expires 2033-01-05 F4 · derivative.exercise_date: This option shall vest in 48 equal monthly installments subject to continued service to the Issuer by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.